CoChat
Sign Up
Cited by 794Redox biology and oxidative stressCancer and biochemical researchBioactive Compounds and Antitumor Agents

Cancer cell killing via ROS: To increase or decrease, that is the question

Open access
Wang, Jie, Yi, Jing·2008·Cancer Biology & Therapy
DOI 10.4161/cbt.7.12.7067
Open this paper in CoChat — free accountOpen PDF

Abstract

Reactive oxygen species (ROS) act as a second messenger in cell signaling and are essential for various biological processes in normal cells. Any aberrance in redox balance may relate to human pathogenesis including cancers. Since ROS are usually increased in cancer cells due to oncogene activation, relative lack of blood supply or other variances and ROS do involve in initiation, progression and metastasis of cancers, ROS are considered oncogenic. Ironically, ROS production is a mechanism shared by all non-surgical therapeutic approaches for cancers, including chemotherapy, radiotherapy and photodynamic therapy, due to their implication in triggering cell death, therefore ROS are also used to kill cancer cells. Because of the double-edged sword property of ROS in determining cell fate, both pro- or anti-oxidant therapies have been proposed for treatments of cancers. Based on either side, a number of drugs, agents and approaches are developed or in the progress of development, some of which have shown clinical promise. This review summarizes the current understanding on ROS-manipulation strategies in cancer treatment and underlying mechanisms. ROS-producing or -eliminating agents and the potential drugs in this aspect are categorized. An effort is made in particular to discuss the paradox in the rationales of two opposite ROS-manipulation strategies and the concerns for their use. Selectivity between tumor and non-tumor cells may depend on difference of their redox environments. A combinational set of cellular parameters including redox status, antioxidant enzymes expression, cell signaling and transcription factor activation profiles, namely "redox signaling signature", is waiting for being developed in order to choose ROS-elevating or ROS-depleting therapy specific to certain type of cancer cells. In clinical setting individualized choice of an optimal ROS-manipulation therapy may require accurate and convenient measurements for ROS as well as "redox signaling signature" for prediction of efficacy and systemic toxicity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/cbt.7.12.7067

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Still being checked.

Research works printed but not linked: 99

  1. [1]1. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008; 266:37-52.
  2. [2]2. Clerkin JS, Naughton R, Quiney C, Cotter TG. Mechanisms of ROS modulated cell sur- vival during carcinogenesis. Cancer Lett 2008; 266:30-6.
  3. [3]3. D'Autreaux B, Toledano MB. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007; 8:813-24.
  4. [4]4. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: A breath of life or death? Clin Cancer Res 2007; 13:789-94.
  5. [5]5. Conklin KA. Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeu- tic effectiveness and development of side effects. Nutr Cancer 2000; 37:1-18.
  6. [6]6. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55:319-21.
  7. [7]7. Liu J, Du J, Zhang Y, et al. Suppression of the malignant phenotype in pancreatic cancer by overexpression of phospholipid hydroperoxide glutathione peroxidase. Hum Gene Ther 2006; 17:105-16.
  8. [8]8. Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM. The induction of human superoxide dismutase and catalase in vivo: A fundamentally new approach to antioxidant therapy. Free Radic Biol Med 2006; 40:341-7.
  9. [9]9. Venkataraman S, Jiang X, Weydert C, et al. Manganese superoxide dismutase overexpres- sion inhibits the growth of androgen-independent prostate cancer cells. Oncogene 2005; 24:77-89.
  10. [10]10. Nishikawa M, Hyoudou K, Kobayashi Y, Umeyama Y, Takakura Y, Hashida M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J Control Release 2005; 109:101-7.
  11. [11]11. Yamagishi S, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by block- ing vascular endothelial growth factor signaling. Am J Pathol 2004; 165:1865-74.
  12. [12]12. Kubo T, Shimose S, Matsuo T, et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 2006; 24:1138-44.
  13. [13]13. Sato K, Yuasa T, Nogawa M, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer 2006; 95:1354-61.
  14. [14]14. Agarwala SS, Sabbagh MH. Histamine dihydrochloride: Inhibiting oxidants and synergis- ing IL-2-mediated immune activation in the tumour microenvironment. Expert Opin Biol Ther 2001; 1:869-79.
  15. [15]15. Soule BP, Hyodo F, Matsumoto K, et al. The chemistry and biology of nitroxide com- pounds. Free Radic Biol Med 2007; 42:1632-50.
  16. [16]16. Neumann CA, Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 2007; 7:375-80.
  17. [17]17. Reinehr R, Becker S, Eberle A, Grether-Beck S, Haussinger D. Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem 2005; 280:27179-94.
  18. [18]18. Medan D, Wang L, Toledo D, et al. Regulation of Fas (CD95)-induced apoptotic and necrotic cell death by reactive oxygen species in macrophages. J Cell Physiol 2005; 203:78-84.
  19. [19]19. Uchikura K, Wada T, Hoshino S, et al. Lipopolysaccharides induced increases in Fas ligand expression by Kupffer cells via mechanisms dependent on reactive oxygen species. Am J Physiol Gastrointest Liver Physiol 2004; 287:620-6.
  20. [20]20. Denning TL, Takaishi H, Crowe SE, Boldogh I, Jevnikar A, Ernst PB. Oxidative stress induces the expression of Fas and Fas ligand and apoptosis in murine intestinal epithelial cells. Free Radic Biol Med 2002; 33:1641-50.
  21. [21]21. Wang X, Zhang J, Xu T. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol Appl Pharmacol 2007; 218:88-95.
  22. [22]22. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002; 3:420-5.
  23. [23]23. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: Signaling for suicide and survival. J Cell Physiol 2002; 192:1-15.
  24. [24]24. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 2002; 90:1259-66.
  25. [25]25. Song JJ, Lee YJ. Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. Biochem J 2003; 373: 845-53.
  26. [26]26. Ryoo K, Huh SH, Lee YH, Yoon KW, Cho SG, Choi EJ. Negative regulation of MEKK1- induced signaling by glutathione S-transferase Mu. J Biol Chem 2004; 279:43589-94.
  27. [27]27. Lee K, Esselman WJ. Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways. Free Radic Biol Med 2002; 33:1121-32.
  28. [28]28. Le Bras M, Clement MV, Pervaiz S, Brenner C. Reactive oxygen species and the mitochon- drial signaling pathway of cell death. Histol Histopathol 2005; 20:205-19.
  29. [29]29. Madesh M, Hajnoczky G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol 2001; 155:1003-15.
  30. [30]30. Costantini P, Belzacq AS, Vieira HL, et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene2000; 19:307-14.
  31. [31]31. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore open- ing during myocardial reperfusion-A target for cardioprotection. Cardiovasc Res 2004; 61:372-85.
  32. [32]32. Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell 2007; 26:675-87.
  33. [33]33. Jacob C, Cottrell GS, Gehringer D, Schmidlin F, Grady EF, Bunnett NW. c-Cbl mediates ubiquitination, degradation and downregulation of human protease-activated receptor 2. J Biol Chem 2005; 280:16076-87.
  34. [34]34. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: Apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18:7719-30.
  35. [35]35. Ramsey MR, Sharpless NE. ROS as a tumour suppressor? Nat Cell Biol 2006; 8:1213-5.
  36. [36]36. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7:97-110.
  37. [37]37. Wu XJ, Hua X. Targeting ROS: Selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound. Cancer Biol Ther 2007; 6:646-7.
  38. [38]38. Giles GI. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006; 12:4427-43.
  39. [39]39. Ozben T. Oxidative stress and apoptosis: Impact on cancer therapy. J Pharm Sci 2007; 96:2181-96.
  40. [40]40. Toler SM, Noe D, Sharma A. Selective enhancement of cellular oxidative stress by chloro- quine: Implications for the treatment of glioblastoma multiforme. Neurosurg Focus 2006; 21:10.
  41. [41]41. Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004; 40:1934-40.
  42. [42]42. Hyoudou K, Nishikawa M, Kobayashi Y, Ikemura M, Yamashita F, Hashida M. SOD deriv- atives prevent metastatic tumor growth aggravated by tumor removal. Clin Exp Metastasis 2008; 25:531-6.
  43. [43]43. Hyoudou K, Nishikawa M, Kobayashi Y, Umeyama Y, Yamashita F, Hashida M. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med 2006; 41:1449-58.
  44. [44]44. Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA. The antioxidant conundrum in cancer. Cancer Res 2003; 63:4295-8.
  45. [45]45. Halliwell B. Oxidative stress and cancer: Have we moved forward? Biochem J 2007; 401:1- 11.
  46. [46]46. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: A marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339:1-9.
  47. [47]47. Hong MY, Turner ND, Carroll RJ, Chapkin RS, Lupton JR. Differential response to DNA damage may explain different cancer susceptibility between small and large intestine. Exp Biol Med (Maywood) 2005; 230:464-71.
  48. [48]48. Chiarugi P. PTPs versus PTKs: The redox side of the coin. Free Radic Res 2005; 39:353- 64.
  49. [49]49. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9:387-99.
  50. [50]50. Kirisits A, Pils D, Krainer M. Epidermal growth factor receptor degradation: An alternative view of oncogenic pathways. Int J Biochem Cell Biol 2007; 39:2173-82.
  51. [51]51. Ravid T, Heidinger JM, Gee P, Khan EM, Goldkorn T. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem 2004; 279:37153-62.
  52. [52]52. Chan DW, Liu VW, Tsao GS, et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008; 29: 1742-50.
  53. [53]53. Laurent A, Nicco C, Chereau C, et al. Controlling tumor growth by modulating endog- enous production of reactive oxygen species. Cancer Res 2005; 65:948-56.
  54. [54]54. Arbiser JL, Petros J, Klafter R, et al. Reactive oxygen generated by Nox1 triggers the angio- genic switch. Proc Natl Acad Sci USA 2002; 99:715-20.
  55. [55]55. Komatsu D, Kato M, Nakayama J, Miyagawa S, Kamata T. NADPH oxidase 1 plays a criti- cal mediating role in oncogenic Ras-induced vascular endothelial growth factor expression. Oncogene 2008; 27:4724-32.
  56. [56]56. Kizaki M, Xian M, Sagawa M, Ikeda Y. Induction of apoptosis via the modulation of reac- tive oxygen species (ROS) production in the treatment of myeloid leukemia. Curr Pharm Biotechnol 2006; 7:323-9.
  57. [57]57. Sanjuan-Pla A, Cervera AM, Apostolova N, et al. A targeted antioxidant reveals the impor- tance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha. FEBS Lett 2005; 579:2669-74.
  58. [58]58. Lim SD, Sun C, Lambeth JD, et al. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 2005; 62:200-7.
  59. [59]59. Jing X, Ueki N, Cheng J, Imanishi H, Hada T. Induction of apoptosis in hepatocellular carcinoma cell lines by emodin. Jpn J Cancer Res 2002; 93:874-82.
  60. [60]60. Ferraro D, Corso S, Fasano E, et al. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 2006; 25:3689-98.
  61. [61]61. Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008; 320:661-4.
  62. [62]62. Mantovani G, Madeddu C, Gramignano G, et al. Subcutaneous interleukin-2 in combina- tion with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: Phase II study evaluating clinical, quality of life and laboratory parameters. J Exp Ther Oncol 2003; 3:205-19.
  63. [63]63. Hellstrand K. Histamine in cancer immunotherapy: A preclinical background. Semin Oncol 2002; 29:35-40.
  64. [64]64. Kong Q, Lillehei KO. Antioxidant inhibitors for cancer therapy. Med Hypotheses 1998; 51:405-9.
  65. [65]65. Siddiqui IA, Adhami VM, Saleem M, Mukhtar H. Beneficial effects of tea and its polyphe- nols against prostate cancer. Mol Nutr Food Res 2006; 50:130-43.
  66. [66]66. Bianchini F, Vainio H. Wine and resveratrol: Mechanisms of cancer prevention? Eur J Cancer Prev 2003; 12:417-25.
  67. [67]67. Seifried HE, Anderson DE, Fisher EI, Milner JA. A review of the interaction among dietary antioxidants and reactive oxygen species. J Nutr Biochem 2007; 18:567-79.
  68. [68]68. Wang Y, Huang X, Cang H, et al. The endogenous reactive oxygen species promote NFkappaB activation by targeting on activation of NFkappaB-inducing kinase in oral squamous carcinoma cells. Free Radic Res 2007; 41:963-71.
  69. [69]69. Huang XZ, Wang J, Huang C, et al. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: The mechanisms involve ROS-mediated suppression of mul- tidrug resistance and hypoxia inducible factor-1(#). Cancer Biol Ther 2007; 7:468-75. 100. Levine AJ, Hu W, Feng Z. The p53 pathway: What questions remain to be explored? Cell Death Differ 2006; 13:1027-36. 101. McCarty MF, Barroso-Aranda J, Contreras F. A two-phase strategy for treatment of oxidant- dependent cancers. Med Hypotheses 2007; 69:489-96. 102. Yang J, Li H, Chen YY, et al. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic Biol Med 2004; 37:2027-41. 103. Kong Q, Kleinschmidt-Demasters BK, Lillehei KO. Intralesionally implanted cisplatin cures primary brain tumor in rats. J Surg Oncol 1997; 64:268-73. 104. Kong Q, Kleinschmidt-DeMasters BK, Lillehei KO. Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. J Surg Oncol 1998; 69:76-82. 105. Jung HA, Chung HY, Yokozawa T, Kim YC, Hyun SK, Choi JS. Alaternin and emodin with hydroxyl radical inhibitory and/or scavenging activities and hepatoprotective activity on tacrine-induced cytotoxicity in HepG2 cells. Arch Pharm Res 2004; 27:947-53. 106. Chen YC, Shen SC, Lee WR, et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 2002; 64:1713-24.
  70. [70]70. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007; 26:1749-60.
  71. [71]71. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol 2007; 17:422-7.
  72. [72]72. Ghavami S, Asoodeh A, Klonisch T, et al. Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J Cell Mol Med 2008; 12:1005-22.
  73. [73]73. Cai J, Niu X, Chen Y, et al. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia 2008; 10:41-51.
  74. [74]74. Scherz-Shouval R, Shvets E, Elazar Z. Oxidation as a post-translational modification that regulates autophagy. Autophagy 2007; 3:371-3.
  75. [75]75. Kramer RA, Zakher J, Kim G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 1988; 241:694-7.
  76. [76]76. Wartenberg M, Hoffmann E, Schwindt H, et al. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS Lett 2005; 579:4541-9.
  77. [77]77. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101:4098-104.
  78. [78]78. Yi J, Gao F, Shi G, et al. The inherent cellular level of reactive oxygen species: One of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 2002; 7:209-15.
  79. [79]79. Yi J, Yang J, He R, et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004; 64:108-16.
  80. [80]80. Engel RH, Evens AM. Oxidative stress and apoptosis: A new treatment paradigm in cancer. Front Biosci 2006; 11:300-12.
  81. [81]81. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 2004; 101:4578-83.
  82. [82]82. Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 2007; 1776:86-107.
  83. [83]83. Solban N, Rizvi I, Hasan T. Targeted photodynamic therapy. Lasers Surg Med. Jun 2006; 38:522-31.
  84. [84]84. Hsieh YJ, Wu CC, Chang CJ, Yu JS. Subcellular localization of Photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: When plasma membranes are the main targets. J Cell Physiol 2003; 194:363-75.
  85. [85]85. Jing Y, Yang J, Wang Y, et al. Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. Free Radic Biol Med 2006; 40:2183-97.
  86. [86]86. Mookerjee A, Basu JM, Majumder S, et al. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer 2006; 6:267.
  87. [87]87. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10:241-52.
  88. [88]88. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003; 17:931-40.
  89. [89]89. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93:268-77.
  90. [90]90. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 2006; 16:420-6.
  91. [91]91. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy. Cancer Biol Ther 2005; 4:6-13.
  92. [92]92. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 defi- ciency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 2006; 281:13005-8.
  93. [93]93. Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ. Disulfiram facilitates intra- cellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004; 47:6914-20.
  94. [94]94. Donate F, Juarez JC, Burnett ME, et al. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolyb- date (ATN-224). Br J Cancer 2008; 98:776-83.
  95. [95]95. Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypotheses 2000; 55:29-35.
  96. [96]96. Jing YW, Yi J, Chen YY, et al. Dicoumarol alters cellular redox state and inhibits nuclear factor kappaB to enhance arsenic trioxide-induced apoptosis. Acta Biochim Biophys Sin (Shanghai) 2004; 36:235-42.
  97. [97]97. Schumacker PT. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 2006; 10:175-6.
  98. [98]98. Shinohara M, Shang WH, Kubodera M, et al. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by downregulating Rho. J Biol Chem 2007; 282:17640-8.
  99. [99]99. Michiels C, Minet E, Mottet D, Raes M. Regulation of gene expression by oxygen: NFkappaB and HIF-1, two extremes. Free Radic Biol Med 2002; 33:1231-42.

Cited by

Sorted by citations

Related

Authors
Wang, J., & Yi, J.
Affiliations
Shanghai Jiao Tong University (CN)
ORCID
Venue
Cancer Biology & Therapy
Publisher
Informa UK Limited
Published
2008-12
Volume
7
Issue
12
Pages
1875-1884
ISSN
  • 1538-4047 (ISSN-L)
  • 1555-8576
DOI
10.4161/cbt.7.12.7067
OpenAlex
W1973206036
Cited by
790
References
0
Citations by year
2026: 22 · 2025: 26 · 2024: 36 · 2023: 62 · 2022: 73 · 2021: 68 · 2020: 58 · 2019: 73 · 2018: 52 · 2017: 54 · 2016: 41 · 2015: 51 · 2014: 48 · 2013: 49 · 2012: 26
FWCI
1.31
Type
journal article
Language
en
Open access
Locations
  • Cancer Biology & Therapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (30570965)
  • Ministry of Science and Technology of the People's Republic of China
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords
reactive oxygen species, cancer cell death, redox signaling, antioxidant therapy, pro-oxidant therapy, redox homeostasis, tumor-selective drug delivery, metastasis, chemotherapy, radiotherapy, photodynamic therapy, antioxidant enzymes, transcription factor activation
MeSH terms
Antineoplastic Agents, Antioxidants, Cell Division, Cell Survival, Humans, Neoplasms, Second Messenger Systems, Signal Transduction, Oxidants, Cell Death, Reactive Oxygen Species

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review